Mirum Pharmaceuticals (MIRM.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec20

Citizens Jmp Raises Mirum Pharmaceuticals Target Price to $140

06:20

Dec19

Mirum Pharmaceuticals Conducts Private Placement to Fund Acquisition of Bluejay Therapeutics

14:01

Dec16

Stifel Maintains Buy Rating on Mirum Pharmaceuticals and Raises Target Price

18:03

Dec8

Mirum Pharmaceuticals to Acquire Bluejay Therapeutics for $620 Million in Cash and Stock

13:02

Dec1

Mirum Pharmaceuticals Launches Phase 2 BLOOM Clinical Trial for Fragile X Syndrome Treatment MRM-3379

13:10

Nov7

Mirum to Present LIVMARLI and Volixibat Clinical Programs at AASLD

13:10

Schedules & Filings

Schedules

Filings

Nov4

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 133.01 M, Net Income 2.905 M, EPS 0.0499

Aug6

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 127.79 M, Net Income -5.861 M, EPS -0.1178

May7

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 111.59 M, Net Income -14.68 M, EPS -0.3002

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change